{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:53:38Z","timestamp":1787320418560,"version":"build-2736575974"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R35 GM122601"],"award-info":[{"award-number":["R35 GM122601"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AG012411"],"award-info":[{"award-number":["AG012411"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 GM098922"],"award-info":[{"award-number":["R01 GM098922"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.bmcl.2018.12.026","type":"journal-article","created":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T04:41:42Z","timestamp":1544676102000},"page":"430-434","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["N-Naphthoyl-substituted indole thio-barbituric acid analogs inhibit the helicase activity of the hepatitis C virus NS3"],"prefix":"10.1016","volume":"29","author":[{"given":"John C.","family":"Marecki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suja","family":"Aarattuthodiyil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia K.","family":"Byrd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narsimha R.","family":"Penthala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Crooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin D.","family":"Raney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2018.12.026_b0005","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"Polaris Observatory HCV Collaborators","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.bmcl.2018.12.026_b0010","doi-asserted-by":"crossref","first-page":"293","DOI":"10.7326\/M13-1133","article-title":"Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010","volume":"160","author":"Denniston","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bmcl.2018.12.026_b0015","doi-asserted-by":"crossref","first-page":"17006","DOI":"10.1038\/nrdp.2017.6","article-title":"Hepatitis C virus infection","volume":"3","author":"Manns","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.bmcl.2018.12.026_b0020","doi-asserted-by":"crossref","first-page":"e1002881","DOI":"10.1371\/journal.ppat.1002881","article-title":"Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate","volume":"8","author":"Ribeiro","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.bmcl.2018.12.026_b0025","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1128\/jvi.67.8.4665-4675.1993","article-title":"Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus","volume":"67","author":"Hijikata","year":"1993","journal-title":"J Virol"},{"key":"10.1016\/j.bmcl.2018.12.026_b0030","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1128\/JVI.80.1.404-411.2006","article-title":"Hepatitis C virus subgenomic replicon requires an active NS3 RNA helicase","volume":"80","author":"Lam","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.bmcl.2018.12.026_b0035","unstructured":"D.N. Frick, HCV Helicase: Structure, Function, and Inhibition, in: S.L. Tan (Ed.) Hepatitis C Viruses: Genomes and Molecular Biology, Norfolk (UK), 2006."},{"key":"10.1016\/j.bmcl.2018.12.026_b0040","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.2741\/4038","article-title":"Superfamily 2 helicases","volume":"17","author":"Byrd","year":"2012","journal-title":"Front Biosci (Landmark Ed)"},{"key":"10.1016\/j.bmcl.2018.12.026_b0045","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1021\/bi901977k","article-title":"Investigation of translocation, DNA unwinding, and protein displacement by NS3h, the helicase domain from the hepatitis C virus helicase","volume":"49","author":"Matlock","year":"2010","journal-title":"Biochemistry"},{"key":"10.1016\/j.bmcl.2018.12.026_b0050","doi-asserted-by":"crossref","first-page":"584","DOI":"10.2174\/1389557517666170913111930","article-title":"Recent Advancement of Direct-acting Antiviral Agents (DAAs) in Hepatitis C Therapy","volume":"18","author":"Das","year":"2018","journal-title":"Mini Rev Med Chem"},{"key":"10.1016\/j.bmcl.2018.12.026_b0055","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.jhep.2018.07.002","article-title":"Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection","volume":"69","author":"Vermehren","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.bmcl.2018.12.026_b0060","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.bmcl.2012.12.053","article-title":"5-((1-Aroyl-1H-indol-3-yl)methylene)-2-thioxodihydropyrimidine-4,6(1H,5H)-diones as potential anticancer agents with anti-inflammatory properties","volume":"23","author":"Penthala","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2018.12.026_b0065","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1021\/cb400305r","article-title":"N-Aroyl indole thiobarbituric acids as inhibitors of DNA repair and replication stress response polymerases","volume":"8","author":"Coggins","year":"2013","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.bmcl.2018.12.026_b0070","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1021\/acs.biochem.7b01176","article-title":"A small-molecule inhibitor of human DNA polymerase eta potentiates the effects of cisplatin in tumor cells","volume":"57","author":"Zafar","year":"2018","journal-title":"Biochemistry"},{"key":"10.1016\/j.bmcl.2018.12.026_b0075","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.3389\/fmicb.2017.02153","article-title":"Identification and Analysis of Novel Inhibitors against NS3 Helicase and NS5B RNA-Dependent RNA Polymerase from Hepatitis C Virus 1b (Con1)","volume":"8","author":"Yang","year":"2017","journal-title":"Front Microbiol"},{"key":"10.1016\/j.bmcl.2018.12.026_b0080","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/bph.13358","article-title":"Identification of a resveratrol tetramer as a potent inhibitor of hepatitis C virus helicase","volume":"173","author":"Lee","year":"2016","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bmcl.2018.12.026_b0085","doi-asserted-by":"crossref","first-page":"8607","DOI":"10.1093\/nar\/gks623","article-title":"Identification and analysis of hepatitis C virus NS3 helicase inhibitors using nucleic acid binding assays","volume":"40","author":"Mukherjee","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.bmcl.2018.12.026_b0090","doi-asserted-by":"crossref","first-page":"18439","DOI":"10.3390\/ijms160818439","article-title":"Identification of Hydroxyanthraquinones as Novel Inhibitors of Hepatitis C Virus NS3 Helicase","volume":"16","author":"Furuta","year":"2015","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmcl.2018.12.026_b0095","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1021\/cb500512z","article-title":"Ebselen inhibits hepatitis C virus NS3 helicase binding to nucleic acid and prevents viral replication","volume":"9","author":"Mukherjee","year":"2014","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.bmcl.2018.12.026_b0100","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1002\/pro.2378","article-title":"The interdomain interface in bifunctional enzyme protein 3\/4A (NS3\/4A) regulates protease and helicase activities","volume":"22","author":"Aydin","year":"2013","journal-title":"Protein Sci"},{"key":"10.1016\/j.bmcl.2018.12.026_b0105","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1128\/JVI.02130-10","article-title":"Unmasking the active helicase conformation of nonstructural protein 3 from hepatitis C virus","volume":"85","author":"Ding","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.bmcl.2018.12.026_b0110","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.jmb.2010.11.034","article-title":"Visualizing ATP-dependent RNA translocation by the NS3 helicase from HCV","volume":"405","author":"Appleby","year":"2011","journal-title":"J Mol Biol"},{"key":"10.1016\/j.bmcl.2018.12.026_b0115","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1093\/emboj\/21.5.1168","article-title":"The hepatitis C viral NS3 protein is a processive DNA helicase with cofactor enhanced RNA unwinding","volume":"21","author":"Pang","year":"2002","journal-title":"EMBO J"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X18309727?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X18309727?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:27:44Z","timestamp":1760772464000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X18309727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0960894X18309727"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2018.12.026","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"N-Naphthoyl-substituted indole thio-barbituric acid analogs inhibit the helicase activity of the hepatitis C virus NS3","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2018.12.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}